423 related articles for article (PubMed ID: 30716472)
1. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
[TBL] [Abstract][Full Text] [Related]
2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
Sato Y; Thomas DY; Hanrahan JW
J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
[TBL] [Abstract][Full Text] [Related]
3. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
[TBL] [Abstract][Full Text] [Related]
4. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
5. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
[TBL] [Abstract][Full Text] [Related]
7. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
[TBL] [Abstract][Full Text] [Related]
8. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
9. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
[TBL] [Abstract][Full Text] [Related]
10. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
11. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
12. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease.
Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
[TBL] [Abstract][Full Text] [Related]
14. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
15. Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
Uliyakina I; Botelho HM; da Paula AC; Afonso S; Lobo MJ; Felício V; Farinha CM; Amaral MD
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630527
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
Stanton BA; Coutermarsh B; Barnaby R; Hogan D
PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
[TBL] [Abstract][Full Text] [Related]
17. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
19. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
20. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
